Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04864600
Other study ID # 201100
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date December 31, 2020

Study information

Verified date April 2021
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

INTRODUCTION: Particle contamination is suggested to have substantial negative effects on health, with candles emitting huge amount of particles, thus being one of the largest contributors to indoor air pollution. Chronic low levels of exposure to indoor particles over time is an important risk factor for the health of the population as a whole and it becomes particularly important for vulnerable groups like people suffering from respiratory diseases such as asthma. AIM: In a randomized controlled cross-over trial the difference in health effects between two candles I) a standard candle and II) a low emission candle modified from the standard candle is studied.


Description:

INTRODUCTION; Particle contamination is suggested to have substantial negative effects on health, with candles emitting the huge amount of particles, thus being one of the largest contributors to indoor air pollution. Chronic low levels of exposure to indoor particles over time is an important risk factor for the health of the population as a whole and it becomes particularly important for vulnerable groups like children and the elderly or people already suffering from allergies and respiratory diseases such as asthma. AIM: To study the difference in health effects between two candles I) a standard candle and II) a low emission candle modified from the standard candle. The following hypothesis will be examined: Short-term exposure to particles generated by the standard candle is associated with more objectively measurable effects in metabolomics inflammation compared to exposure to modified low-emission candle particles. METHODS: Separated by two weeks 20 young asthmatics will be exposed in a randomized cross-over double-blind study under controlled conditions in a climate chamber to three different exposures; A) a standard (Scandinavian) stearin candle, B) a modified low emitting version of the same candle, and C) clean air from the adjacent chamber. The experiment will be carried out in groups of 3-6 participants. MEASUREMENTS: TSI P-TRAK Ultrafine Particle Counter and SMPS will be used for particle counts. Health effects, including spirometry and fraction of exhaled nitric oxide (FeNO) will be evaluated in relation to local and systemic effects prior to, right after and 24 h. after exposure. ANALYSIS: Mixed methods approach taking both time and exposure into account.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - Age 18-25 - Medically treated / physician diagnosed mild seasonal asthma GINA guidelines step 1 or 2 (https://ginasthma.org/) - Never smoker or ex-smoker = 6 months - Allergy > 1 common allergy Exclusion Criteria: - Any other disease that could influence the study parameters - Conditions that prevent safe access to the climate chambers (such as claustrophobia) - Perennial asthma - Need for continuous medical treatment for asthma - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Candle C
Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
Candle 1
Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.

Locations

Country Name City State
Denmark Climate Chambers, Dept. Public Health, Aarhus University Aarhus Central Region Denmark

Sponsors (10)

Lead Sponsor Collaborator
University of Aarhus ASP-HOLMBLAD A/S, COOP Denmark, Danish Technological Institute, Danwax, European Candle Association, Liljeholmens Stearinfabrik, Lund University, Promol, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Particles in Exhaled Air (Surfactant Protein A & Albumin) PExA: Subjects performed repeated breath maneuvers allowing for airway closure and re-opening, and exhaled particles were optically counted and collected on a membrane using the PExA® instrument set-up At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in Lung Function (FEV1 & FVC) Spirometry At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in Fractional exhaled nitric oxide (FENO) NIOX VERO system; Aerocrine AB, Sweden At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in white blood cells in Blood White blood cells At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in Endothelial Progenitor Cells (EPCs) in Blood Endothelial progenitor cells (EPC) further divided into early and late EPCs At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in inflammatory markers in Blood Interleukin 8, interleukin 1 At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in biomarkers in Blood Metabolomics At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in nasal volume (using Acoustic rhinometry) Acoustic rhinometry is used to assess the nasal cross sectional area and volume. The left and right nasal cavity were studied alternatively until three reproducible measurements were obtained. The minimum cross sectional cavity area is calculated from the means of the measurements. By integration of the area-distance curve, the sum of the volume 2 to 4 (vol2-4) from the nostril is determined on both sides. At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in biomarkers in Saliva Sample An oral svap from Salivette was placed in the mouth of the participant to collect saliva by gently chewing the swab for one minute. Afterwards the saturated swab was removed to the suspended insert and closed firmly with a lid. Then the sample was transferred to a freezer and stored for -80 C until further analysis. The sample will be analyzed for biomarkers (amylase, cortisol, substance P, lysozyme and secretory IgA. (same unit measure)) after exposure (5 hours), and the day after exposure (24 hours)
Secondary ReCIVA Sampling of VOCs and particles in exhaled air. Breathing through a mask for 10-15 minutes makes it possible to collect VOCs and particles into tenax air sampling tubes. At baseline (0 hour), after exposure (5 hours), and the day after exposure (24 hours)
Secondary Change in Subjective Symptoms n the exposure chamber participants are asked to fill out a symptom questionnaire every 30 minute regarding their well-being and experienced symptoms in eyes, nose and throat. The participants are asked to score their evaluation / rate the strength of symptoms on a Linear Numeric Scale from 0-10, with 10 being worst. Health effects are evaluated in relation to rated changes in symptoms Every 30 minute during 5 hours of exposure
Secondary Heart rate using a Fitbit Using a Fitbit watch participants' heart rate is measured. From exposure start until the morning after exposure (in total 24 hours)
Secondary Sleep quality using a Fitbit Using a Fitbit watch participants' sleep quality is measured. during 48 hours
See also
  Status Clinical Trial Phase
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Not yet recruiting NCT05990933 - Role of Adrenaline in in the Inflammatory Response in Diabetes N/A
Not yet recruiting NCT06016023 - Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
Not yet recruiting NCT04608643 - Inflammatory Markers and Cbc Indices in Severely Malnourished Children
Recruiting NCT01934049 - Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty Phase 4
Recruiting NCT01417923 - The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Phase 4
Terminated NCT01377441 - Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia. Phase 4
Completed NCT01301079 - Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Phase 3
Terminated NCT00578578 - Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Phase 4
Recruiting NCT04611334 - The Effects of HRV Biofeedback on Chronic Kidney Disease Patient. N/A
Recruiting NCT03510702 - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed NCT03445234 - Blueberries, Bananas, Exercise Recovery N/A
Not yet recruiting NCT05754294 - Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
Not yet recruiting NCT04386525 - Omega 3 and Ischemic Stroke; Fish Oil as an Option Phase 4
Completed NCT04014439 - Relationship Between NLR and Prealbumin Levels With Diaphragm Thickness
Active, not recruiting NCT03002259 - Dexamethasone for Cardiac Surgery-II Trial Phase 4
Not yet recruiting NCT03245684 - Assisted or Controlled Ventilation in Ards (Ascovent) N/A